Guardian Investment Management Has $3.25 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Guardian Investment Management lessened its stake in Johnson & Johnson (NYSE:JNJ) by 12.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 20,022 shares of the company’s stock after selling 2,800 shares during the period. Johnson & Johnson comprises 2.6% of Guardian Investment Management’s portfolio, making the stock its 9th biggest holding. Guardian Investment Management’s holdings in Johnson & Johnson were worth $3,245,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in JNJ. Innealta Capital LLC bought a new stake in shares of Johnson & Johnson in the second quarter valued at about $27,000. MFA Wealth Advisors LLC bought a new stake in shares of Johnson & Johnson in the second quarter valued at about $43,000. Fairfield Financial Advisors LTD bought a new stake in shares of Johnson & Johnson in the second quarter valued at about $46,000. Grayhawk Investment Strategies Inc. raised its position in Johnson & Johnson by 528.6% in the fourth quarter. Grayhawk Investment Strategies Inc. now owns 308 shares of the company’s stock worth $48,000 after purchasing an additional 259 shares in the last quarter. Finally, Fairway Wealth LLC raised its position in Johnson & Johnson by 217.1% in the second quarter. Fairway Wealth LLC now owns 333 shares of the company’s stock worth $49,000 after purchasing an additional 228 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently issued reports on JNJ. Royal Bank of Canada increased their price target on shares of Johnson & Johnson from $175.00 to $178.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 8th. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a research report on Thursday. TD Securities dropped their price target on shares of Johnson & Johnson from $195.00 to $185.00 in a research report on Thursday, July 18th. The Goldman Sachs Group dropped their price objective on shares of Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating for the company in a report on Friday, July 19th. Finally, StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, September 14th. Six investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $174.31.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of the firm’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the transaction, the vice president now directly owns 18,973 shares of the company’s stock, valued at approximately $3,131,683.38. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Price Performance

Shares of JNJ traded up $0.95 during mid-day trading on Friday, hitting $161.46. 5,253,459 shares of the company traded hands, compared to its average volume of 7,039,524. Johnson & Johnson has a one year low of $143.13 and a one year high of $168.85. The company has a current ratio of 1.07, a quick ratio of 0.85 and a debt-to-equity ratio of 0.44. The business has a 50-day moving average of $162.59 and a 200 day moving average of $154.48. The stock has a market capitalization of $388.58 billion, a price-to-earnings ratio of 10.07, a PEG ratio of 2.65 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, July 17th. The company reported $2.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.71 by $0.11. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The firm had revenue of $22.45 billion for the quarter, compared to analysts’ expectations of $22.33 billion. During the same period last year, the firm earned $2.80 earnings per share. The business’s revenue for the quarter was up 4.3% on a year-over-year basis. As a group, equities analysts expect that Johnson & Johnson will post 10 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th were paid a $1.24 dividend. The ex-dividend date of this dividend was Tuesday, August 27th. This represents a $4.96 dividend on an annualized basis and a yield of 3.07%. Johnson & Johnson’s payout ratio is presently 30.92%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.